Letter to the editor: switching treatment to lamivudine plus boosted atazanavir or darunavir in virologically suppressed HIV-infected patients–evidence from a large observational cohort

D. F. Bavaro; D. Di Carlo; P. Zuccalà; F. Bai; F. Incardona; A. Battisti; S. Giachè; E. Salomoni; R. Gagliardini; Simona Di Giambenedetto; M. Pecorari; M. Zazzi; A. De Luca; Andrea De Luca; A. Bezenchek; S. Lo Caputo

doi:10.1080/23744235.2018.1544423

Letter to the editor: switching treatment to lamivudine plus boosted atazanavir or darunavir in virologically suppressed HIV-infected patients–evidence from a large observational cohort

D. F. Bavaro, D. Di Carlo, P. Zuccalà, F. Bai, F. Incardona, A. Battisti, S. Giachè, E. Salomoni, R. Gagliardini, Simona Di Giambenedetto, M. Pecorari, M. Zazzi, A. De Luca, Andrea De Luca, A. Bezenchek, S. Lo Caputo

Risultato della ricerca: Contributo in rivista › Articolo in rivista

Abstract

letter, not available

Lingua originale	English
pagine (da-a)	234-239
Numero di pagine	6
Rivista	Infectious Diseases
Volume	51
DOI	https://doi.org/10.1080/23744235.2018.1544423
Stato di pubblicazione	Pubblicato - 2019

Keywords

Antiretroviral Therapy, Highly Active
Atazanavir Sulfate
Darunavir
HIV
HIV Infections
Humans
Lamivudine
Ritonavir

OSS delle Nazioni Unite

Questo processo contribuisce al raggiungimento dei seguenti obiettivi di sviluppo sostenibile

Accesso al documento

10.1080/23744235.2018.1544423

Altri file e collegamenti

Cita questo

Bavaro, D. F., Di Carlo, D., Zuccalà, P., Bai, F., Incardona, F., Battisti, A., Giachè, S., Salomoni, E., Gagliardini, R., Di Giambenedetto, S., Pecorari, M., Zazzi, M., De Luca, A., De Luca, A., Bezenchek, A., & Lo Caputo, S. (2019). Letter to the editor: switching treatment to lamivudine plus boosted atazanavir or darunavir in virologically suppressed HIV-infected patients–evidence from a large observational cohort. Infectious Diseases, 51, 234-239. https://doi.org/10.1080/23744235.2018.1544423

@article{4ab17566ce4b4c3c8e29fe683dab07a7,

title = "Letter to the editor: switching treatment to lamivudine plus boosted atazanavir or darunavir in virologically suppressed HIV-infected patients–evidence from a large observational cohort",

abstract = "letter, not available",

keywords = "Antiretroviral Therapy, Highly Active, Atazanavir Sulfate, Darunavir, HIV, HIV Infections, Humans, Lamivudine, Ritonavir, Antiretroviral Therapy, Highly Active, Atazanavir Sulfate, Darunavir, HIV, HIV Infections, Humans, Lamivudine, Ritonavir",

author = "Bavaro, {D. F.} and {Di Carlo}, D. and P. Zuccal{\`a} and F. Bai and F. Incardona and A. Battisti and S. Giach{\`e} and E. Salomoni and R. Gagliardini and {Di Giambenedetto}, Simona and M. Pecorari and M. Zazzi and {De Luca}, A. and {De Luca}, Andrea and A. Bezenchek and {Lo Caputo}, S.",

year = "2019",

doi = "10.1080/23744235.2018.1544423",

language = "English",

volume = "51",

pages = "234--239",

journal = "Infectious Diseases",

issn = "2374-4235",

publisher = "London: Taylor & Francis",

}

Bavaro, DF, Di Carlo, D, Zuccalà, P, Bai, F, Incardona, F, Battisti, A, Giachè, S, Salomoni, E, Gagliardini, R, Di Giambenedetto, S, Pecorari, M, Zazzi, M, De Luca, A, De Luca, A, Bezenchek, A & Lo Caputo, S 2019, 'Letter to the editor: switching treatment to lamivudine plus boosted atazanavir or darunavir in virologically suppressed HIV-infected patients–evidence from a large observational cohort', Infectious Diseases, vol. 51, pagg. 234-239. https://doi.org/10.1080/23744235.2018.1544423

TY - JOUR

T1 - Letter to the editor: switching treatment to lamivudine plus boosted atazanavir or darunavir in virologically suppressed HIV-infected patients–evidence from a large observational cohort

AU - Bavaro, D. F.

AU - Di Carlo, D.

AU - Zuccalà, P.

AU - Bai, F.

AU - Incardona, F.

AU - Battisti, A.

AU - Giachè, S.

AU - Salomoni, E.

AU - Gagliardini, R.

AU - Di Giambenedetto, Simona

AU - Pecorari, M.

AU - Zazzi, M.

AU - De Luca, A.

AU - De Luca, Andrea

AU - Bezenchek, A.

AU - Lo Caputo, S.

PY - 2019

Y1 - 2019

N2 - letter, not available

AB - letter, not available

KW - Antiretroviral Therapy, Highly Active

KW - Atazanavir Sulfate

KW - Darunavir

KW - HIV

KW - HIV Infections

KW - Humans

KW - Lamivudine

KW - Ritonavir

KW - Antiretroviral Therapy, Highly Active

KW - Atazanavir Sulfate

KW - Darunavir

KW - HIV

KW - HIV Infections

KW - Humans

KW - Lamivudine

KW - Ritonavir

UR - http://hdl.handle.net/10807/140089

UR - http://www.tandfonline.com/loi/infd20#.vrgcoldf1fo

U2 - 10.1080/23744235.2018.1544423

DO - 10.1080/23744235.2018.1544423

M3 - Article

SN - 2374-4235

VL - 51

SP - 234

EP - 239

JO - Infectious Diseases

JF - Infectious Diseases

ER -

Letter to the editor: switching treatment to lamivudine plus boosted atazanavir or darunavir in virologically suppressed HIV-infected patients–evidence from a large observational cohort

Abstract

Keywords

OSS delle Nazioni Unite

Accesso al documento

Altri file e collegamenti

Fingerprint

Cita questo